Covid-19

Covid-19 | OMS afirma que o segundo reforço de vacina pode ser benéfico em grupos de alto risco, mas tem um impacto “mínimo” para outros grupos.

23 Mai, 2022 | 13:31h

Covid-19: Second boosters may benefit at-risk groups but have “minimal” impact for others, says WHO – The BMJ

Diretriz original: Interim statement on the use of additional booster doses of Emergency Use Listed mRNA vaccines against COVID-19 – World Health Organization

Recomendações relacionadas:

COVID-19: Joint statement from ECDC and EMA on the administration of a fourth dose of mRNA vaccines –
European Centre for Disease Prevention and Control

Coronavirus (COVID-19) Update: FDA Authorizes Second Booster Dose of Two COVID-19 Vaccines for Older and Immunocompromised Individuals – U.S. Food & Drug Administration

---

Reativação sanguínea do citomegalovírus em pacientes críticos com COVID-19: fatores de risco e impacto sobre a mortalidade.

23 Mai, 2022 | 13:29h

Cytomegalovirus blood reactivation in COVID-19 critically ill patients: risk factors and impact on mortality – Intensive Care Medicine

 

Comentário no Twitter

CMV reactivation in #COVID19 critically ill pts:
🦠frequent! >20% in this study
🧪risk depends on severity of illness/occurrence of secondary bacterial infections in #ICU
🏥 prolonged hospital stay & higher mortality but independent association lacking.
📎 https://t.co/N8JVD1GyPQ pic.twitter.com/KYRtLmxtJg

— Intensive Care Medicine (@yourICM) May 18, 2022

 

---

Opinião | Paxlovid ajuda as pessoas vacinadas contra Covid-19? Mostrem-nos os dados!

20 Mai, 2022 | 14:10h

Does Paxlovid help people who have been vaccinated against Covid-19? Show us the data! – STAT

---

Revisão | Síndromes infecciosas pós-agudas inexplicadas.

20 Mai, 2022 | 14:07h

Unexplained post-acute infection syndromes – Nature Medicine (se o acesso a este link for pago, tente este)

 

Comentário no Twitter

A @NatureMedicine tour de force review of the unexplained post-acute infectious syndromes, which includes #LongCovid and many others https://t.co/5RnyY9l0eQ
by @jan_choutka @mhornig @VirusesImmunity pic.twitter.com/dhYeZYnM1U

— Eric Topol (@EricTopol) May 18, 2022

 

---

Opinião | Bill Gates e o destino da OMS.

20 Mai, 2022 | 14:05h

Offline: Bill Gates and the fate of WHO – The Lancet

 

Comentário no Twitter

Offline: Bill Gates and the fate of WHO https://t.co/KKUkdFteUN An oped by @richardhorton1 in @TheLancet which he criticizes both @BillGates & @WHO on their positions to the future of pandemic responses.

— Carlos del Rio (@CarlosdelRio7) May 13, 2022

 

---

OMS | Segundo reforço da vacina contra COVID para os mais vulneráveis oferece benefícios.

19 Mai, 2022 | 13:15h

WHO: 2nd COVID booster for most vulnerable offers benefits – World Health Organization

---

Cães farejadores na detecção de COVID-19: estudo randomizado triplo-cego em ambiente aeroportuário.

19 Mai, 2022 | 13:14h

Scent dogs in detection of COVID-19: triple-blinded randomised trial and operational real-life screening in airport setting – BMJ Global Health

Comunicado de imprensa: Trained sniffer dogs accurately detect people infected with SARS-CoV-2 – BMJ Newsroom

Comentário: Trained scent dogs detect airline travelers with COVID-19 – CIDRAP

---

[Preprint] Efetividade do segundo reforço da vacina contra COVID-19 sobra a mortalidade por todas as causas em residentes de instituições de cuidado de longo prazo e em idosos mais velhos: estudo nacional de coorte retrospectiva na Suécia.

19 Mai, 2022 | 13:13h

Effectiveness of a Second COVID-19 Vaccine Booster on All-Cause Mortality in Long-Term Care Facility Residents and in the Oldest Old: A Nationwide, Retrospective Cohort Study in Sweden – Preprints with The Lancet

 

Comentário no Twitter

Confirmation of the 2nd booster protection from death in people age 80+ in Sweden, with a relative vaccine effectiveness 42% (compared w/ the 1st booster)https://t.co/Dq1x00J3Tr pic.twitter.com/fyXJPEcQzC

— Eric Topol (@EricTopol) May 17, 2022

 

---

Tratamento das interações medicamentosas com nirmatrelvir/ritonavir (Paxlovid).

19 Mai, 2022 | 13:08h

Management of Drug Interactions With Nirmatrelvir/Ritonavir (Paxlovid®): Resource for Clinicians – Infectious Diseases Society of America

Comentário: IDSA offers guidance on managing drug interactions with nirmatrelvir/ritonavir – ACP Internist

Conteúdos relacionados:

Paxlovid’s failure as a preventative measure raises questions, but doctors still back it as a therapeutic – STAT

Yes, Relapses After Paxlovid Happen — Now What? – HIV and ID Observations

Covid-19: What is the evidence for the antiviral Paxlovid? – The BMJ

Yes, Relapses After Paxlovid Happen — Now What? – HIV and ID Observations

WHO recommends highly successful COVID-19 therapy and calls for wide geographical distribution and transparency from originator – World Health Organization

A living WHO guideline on drugs for covid-19 – The BMJ

Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19 – New England Journal of Medicine

Prescribing Nirmatrelvir–Ritonavir: How to Recognize and Manage Drug–Drug Interactions – Annals of Internal Medicine

The COVID-19 Treatment Guidelines Panel’s Statement on Potential Drug-Drug Interactions Between Ritonavir-Boosted Nirmatrelvir (Paxlovid) and Concomitant Medications – NIH COVID-19 Treatment Guidelines Panel

---

Atualização clínica da COVID-19 para o médico emergencista: parada cardíaca dentro e fora do ambiente hospitalar.

18 Mai, 2022 | 17:01h

Clinical update on COVID-19 for the emergency clinician: Cardiac arrest in the out-of-hospital and in-hospital settings – The American Journal of Emergency Medicine

Conteúdos relacionados:

Clinical update on COVID-19 for the emergency and critical care clinician: Medical management – American Journal of Emergency Medicine

Clinical update on COVID-19 for the emergency clinician: Presentation and evaluation – The American Journal of Emergency Medicine

---